StockAnalyst
/
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

来源：Reuters发布于 2026-09-29

Jiangsu Hengrui Pharmaceuticals , China's ​largest drugmaker by ‌market value, said on Tuesday it ​will license ​global rights to ⁠its weight-management drug ​HRS-1596 to ​Novo Nordisk A/S in a deal w...

相关标的：NVO
继续访问返回新闻

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。